glp 1 receptor agonists for type 2 diabetes GLP-1 in the treatment of e GLP-1-based therapies for type 2

[35] reported that a 6-month exenatide-based therapy produced a 42% relative reduction in intrahepatic lipid content, accompanied by a mean BW loss of 5 kg and significant decreases in both abdominal subcutaneous and visceral fat volumes

The Evolution of GLP-1RA Usage GLP-1RA drugs have been used in clinical practice since the mid-2000s

Remember that these estimates are speculative

doi: 10.2337/dc15-0165

Funding Open access funding provided by Centre Hospitalier Universitaire de Lille

Regarding other GLP-1RAs, such as liraglutide and albiglutide, no dose adjustment is necessary in patients with renal impairment, as these drugs are not renally excreted